Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada

INTRODUCTION: While no direct comparative data exist for crizotinib in ROS1+ non-small cell lung cancer (NSCLC), studies have suggested clinical benefit with this targeted agent. The objective of this study was to assess the cost-effectiveness of crizotinib compared to standard platinum-doublet chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Beca, Jaclyn M., Walsh, Shaun, Raza, Kaiwan, Hubay, Stacey, Robinson, Andrew, Mow, Elena, Keech, James, Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556902/
https://www.ncbi.nlm.nih.gov/pubmed/34715804
http://dx.doi.org/10.1186/s12885-021-08746-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556902/
https://www.ncbi.nlm.nih.gov/pubmed/34715804
http://dx.doi.org/10.1186/s12885-021-08746-z

Ejemplares similares